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Histogenesis-speciﬁc expression of ﬁbroblast activation protein and dipeptidylpeptidase-IV
in human bone and soft tissue tumours
Aims: Fibroblast activation protein (FAP) ⁄ seprase and
dipeptidylpeptidase-IV (DPP-IV) ⁄ CD26 are serine inte-
gral membrane proteases. They are involved in tissue
remodelling, cancer invasion and metastases, mecha-
nisms that are controversial. The aim was to identify
cell types that express FAP and DPP-IV in human bone
and soft tissue tumours, and to determine whether
there are any correlations between the expression of
FAP and DPP-IV and the malignant potential of
tumours.
Methods and results: This study analysed in situ expres-
sion in 25 malignant and 13 benign human bone and
soft tissue tumours. Reverse transcriptase-polymerase
chain reaction analyses conﬁrmed mRNA expression of
FAP and DPP-IV in all individuals. Immunohistochem-
istry using pre-ﬁxed frozen sections revealed that FAP
was positive in low-grade myoﬁbroblastic sarcoma, the
ﬁbroblasticcomponentofosteosarcomas,andmalignant
ﬁbrous histiocytomas, but negative in Ewing’s sarcomas
and rhabdomyosarcomas. DPP-IV showed similar
immunohistochemical results. Among benign tumours,
non-ossifying ﬁbromas, desmoid tumours and chond-
roblastomas expressed both FAPand DPP-IV.Giantcells
expressed DPP-IV in giant cell tumours.
Conclusions: Our data suggest that FAP and DPP-IV are
consistently expressed in bone and soft tissue tumour
cells that are histogenetically related to activated
ﬁbroblasts and ⁄ or myoﬁbroblasts, irrespective of their
malignancy. DPP-IV is also expressed in monocyte–
macrophage lineage cells.
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Introduction
Fibroblast activation protein (FAP) ⁄ seprase is a serine
integral membrane proteinase. The molecular weight of
FAPiseither95or97 kDaasamonomerand170 kDaas
a dimer. The dimer shows gelatinolytic activity.
1,2 FAP
is reported as an antigen that is recognized by antibody
F19.
3,4 FAP is not expressed in normal ﬁbroblasts or
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expressed in activated ﬁbroblasts,
5–8 including stromal
ﬁbroblasts in human cancers
9 and granulation tissue
associated with wound healing.
1 Dipeptidylpeptidase-IV
(DPP-IV) ⁄ CD26 hasamolecularweightof105 kDaand
is also a serine integral membrane proteinase. It is an
activation antigen of T lymphocytes. It is diffusely
positive in cells of the proximal tubules of the kidney,
smallintestinalmucosa,bileducts,sinusoidalliningcells
of the spleen, subsets of vascular endothelial cells and
ﬁbroblasts.
7 Since FAP and DPP-IV are both serine
proteases, attention has focused on their potential to
promote cancer cell invasion and metastasis, although
the results of such studies are controversial.
7,10–13 Both
FAP and DPP-IV are abundantly expressed in the
stroma of >90% of breast, colorectal and lung carcin-
omas.
7,14,15 FAP and DPP-IV are also expressed in
sarcomas.
7 However, detailed cell identiﬁcation has not
been performed for these two proteases in sarcomatous
tissues. Furthermore, the relationship between the
expression of these two proteinases and the malignancy
of tumours has not been clariﬁed.
The present study was designed to identify cell types
that express FAP and DPP-IV in human bone and soft
tissue tumours, and to determine whether there are
any correlations between the expression of FAP and
DPP-IV and the malignant potential of tumours.
Materials and methods
Forty-one bone and soft tissue tumours were analysed.
All specimens were obtained by open biopsy or surgical
resection from patients, none of whom had received
radiation orchemotherapy.Alltumours werediagnosed
on the basis of clinical features, imaging, conventional
histopathology and immunohistochemistry of parafﬁn-
embedded sections. There were 26 malignant and 15
benign tumours: 11 osteosarcomas (eight osteoblastic,
two ﬁbroblastic, one chondroblastic), four Ewing’s sar-
comas, four malignant ﬁbrous histiocytomas (MFH) of
pleomorphic type (undifferentiated high-grade pleomor-
phicsarcoma),tworhabdomyosarcomas,twolow-grade
myoﬁbroblastic sarcomas,
16 one adamantinoma, four
giant cell tumours, three schwannomas, one non-
ossifying ﬁbroma, one osteoid osteoma, one desmoid
tumour, one chondroblastoma, one lipoma, and one
elastoﬁbroma. Fibrous granulation tissue obtained from
fourdecubitusulcerswereusedaspositivecontrols.
7Soft
tissues without tumour invasion were used as normal
controls, which were removed with the sarcomas. Of
these, the two cases of low-grade myoﬁbroblastic sar-
coma were originally diagnosed as ‘leiomyosarcoma’.
The reasons for the change of diagnosis included
(i) expression of smooth muscle actin is common to low-
grademyoﬁbroblasticsarcomaandleiomyosarcoma,and
(ii) the tumour cells in the two cases lacked enhanced
cytoplasmic eosinophilia or blunt-ended nuclei, and did
not express calponin on immunohistochemistry.
17,18
mRNA analyses were performed on all specimens
according to the method described by Katou et al.
19
The primer sequences were as follows: FAP: +5-
GCTAACTTTCAAAAACATCTGGAAAAATG-3 (sense)
and +5-GTAATATGTTGCTGTGTAAGAGTATCTCC-3
(anti-sense), and DPP-IV: +5-CTAACTGGACTGGTTC-
AAATGTTGT-3 (sense) and +5-CAGGGCAAGCTGAT-
GTGTTCACATCTC-3 (anti-sense).
For immunohistochemistry, specimens were ﬁxed in
periodate–lysine 4% paraformaldehyde for 6–8 h at
4 C. After washing in phosphate-buffered saline, the
ﬁxed specimens were frozen. Primary antibodies were
mouse monoclonal anti-FAP (clone F19),
9 rat mono-
clonal anti-FAP (clone D8)
20 and mouse monoclonal
anti-DPP-IV (anti-CD26) (clone M-A261; Pharmingen,
San Diego, CA, USA). Envision Plus was used as the
secondary antibody (Dako, Tokyo, Japan). Isotype-
matched control mouse monoclonal antibodies (Dako)
were used as the negative control.
The US Food and Drug Administration-approved
scoring system for HER2 protein was adopted for
semiquantiﬁcation of the localization patterns of FAP
and DPP-IV because the immunoreactivity of both
proteases along the cell membrane is similar to that of
HER2.
21 In brief: score 0, negative or positive in <10%
of tumour cells; score 1+, weakly positive in >10% of
tumour cells; score 2+, moderately positive in >10% of
tumour cells; and score 3+, strongly positive in >10%
of tumour cells.
Results
confirmation of the expression of fap and
dpp-iv in sarcomatous tissue
Reverse transcriptase-polymerase chain reaction anal-
yses identiﬁed the expression of mRNAs for both FAP
and DPP-IV in all specimens examined (Figure 1).
Direct sequencing conﬁrmed the reaction products as
FAP and DPP-IV by referring to the home page of the
National Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov/) (Bethesda, MD, USA).
both fap and dpp-iv are expressed mainly in
spindle-shaped cells
To identify the cell types, immunohistochemistry
was performed using pre-ﬁxed frozen sections, not
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attain more reliable sensitivity, and the results analy-
sed using the semiquantiﬁcation method (Table 1). For
malignant tumours, we analysed low-grade myoﬁbrob-
lastic sarcoma, osteosarcomas, MFH, rhabdomyosar-
coma, Ewing’s sarcoma, and adamantinoma. FAP and
DPP-IV were strongly positive in both cases of low-
grade myoﬁbroblastic sarcoma, and the positive cells
were uniformly spindle-shaped tumour cells (Figure 2).
All of the 11 osteosarcomas also expressed FAP and
DPP-IV. As summarized in Table 1, it is notable that
positive cells for FAP and DPP-IV were observed
speciﬁcally in ﬁbroblastic areas (Figure 3), whereas
they were sparse in osteoblastic (Figure 4) and chond-
roblastic areas. The positive cells in ﬁbroblastic areas
were spindle-shaped ﬁbroblastic tumour cells. FAP and
DPP-IV were also positive in ﬁbroblastic tumour cells in
two of four and four of four MFHs, respectively. In
contrast, no tumour cells expressed FAP or DPP-IV in
four Ewing’s sarcomas, two rhabdomyosarcomas, or
one adamantinoma. However, it should be noted that
reactive ﬁbroblasts in the ﬁbrous septum of all four
Ewing’s sarcomas expressed FAP and DPP-IV moder-
ately to weakly (Figure 5). In addition to ﬁbroblastic
cells, DPP-IV was also expressed in osteoclast-like giant
cells in ﬁve of 11 osteosarcomas.
We then analysed benign tumours to conﬁrm the
expression of FAP and DPP-IV. To analyse giant cell
tumours, we subdivided the cellular components into
giant cells, mononuclear round cells, and spindle-
shaped ﬁbroblastic cells. As summarized in Table 1, all
these components of giant cell tumours expressed FAP
and DPP-IV (Figure 6). FAP and DPP-IV were also
positive in spindle-shaped tumour cells of one non-
ossifying ﬁbroma (Figure 7), one chondroblastoma,
and one desmoid tumour. Osteoclast-like giant cells
were positive for FAP and DPP-IV in one osteoid
FAP
(419 bp)
12 3 4 5 6 7
DPP-IV
(500 bp)
HKG
(450 bp)
Figure 1. Results of reverse transcriptase-polymerase chain reaction
analyses. Lanes: 1, low-grade myoﬁbroblastic sarcoma (case 1);
2, low-grade myoﬁbroblastic sarcoma (case 2); 3, Ewing’s sarcoma;
4, osteosarcoma (a ﬁbroblastic type); 5, osteosarcoma (osteoblastic
type); 6, granulation tissue; 7, RNA()); and HKG, housekeeping
gene.
Table 1. Results of immunohistochemistry
Diagnosis
(number of cases) Case
Score
FAP DPP-IV
Low-grade myoﬁbroblastic
sarcoma (N =2 )
13 3
23 2
Osteosarcoma 3 F 2 2
Fibroblastic
type (N =2 )
O1 0
C0 0
4F 2 0
O1 0
C0 0
Osteoblastic
type (N =8 )
5F 2 0
O0 0
C- -
6F 3 3
O1 1
C- -
7F 3 3
O1 0
C- -
8F 2 2
O0 1
C0 0
9F 1 2
O0 1
C0 0
10 F 2 3
O0 0
C0 0
11 F 1 3
O0 0
C- -
12 F 2 3
O0 0
C0 0
434 O Dohi et al.
  2009 The Authors. Journal compilation   2009 Blackwell Publishing Ltd, Histopathology, 55, 432–440.osteoma. Spindle cells expressed FAP and DPP-IV in
one of three schwannomas. No tumour cells expressed
FAP or DPP-IV in lipoma or elastoﬁbroma.
Discussion
The present study has clearly shown that ﬁbroblast-
like spindle tumour cells strongly express FAP and
DPP-IV in low-grade myoﬁbroblastic sarcoma, ﬁbro-
blastic areas of osteosarcoma, MFH, non-ossifying
ﬁbroma, desmoid tumour, and chondroblastoma. The
expression pattern is similar to that of activated
ﬁbroblasts and ⁄ or myoﬁbroblasts in granulation tis-
sue. In contrast, neither FAP nor DPP-IV is expressed
in round or oval cells in Ewing’s sarcoma or rhabdo-
myosarcoma.
Our results demonstrate the following two points.
First, expression of FAP and DPP-IV is clearly indepen-
dent of the malignant potential of the tumours. Second,
it is rather related to the histogenesis of the tumour
cells, i.e. positive tumour cells are related to activated
ﬁbroblasts and ⁄ or myoﬁbroblasts. Myoﬁbroblasts are
activated ﬁbroblasts that have some of the character-
istics of smooth muscle cells, such as contractile
properties.
22 Eyden has described how tumour cells
with complete myoﬁbroblastic differentiation show
immunoreactivity for smooth muscle actin, prominent
rough endoplasmic reticulum, peripheral smooth-mus-
cle type myoﬁlaments, and ﬁbronexus junctions. It is
Table 1. (Continued)
Diagnosis
(number of cases) Case
Score
FAP DPP-IV
Chondroblastic
type (N =1 )
13 F 1 2
O0 0
C0 0
Malignant ﬁbrous
histiocytoma (N =4 )
14 0 3
15 0 3
16 3 3
17 2 3
Rhabdomyosarcoma
(N =4 )
18 0 0
19 0 0
Ewing’s sarcoma
(N =4 )
20 0 0
21 0 0
22 0 0
23 0 0
Adamantinoma
(N =1 )
24 0 0
Non-ossifying
ﬁbroma (N =1 )
26 3 3
Giant cell tumor
(N =4 )
27 G 1 3
M2 1
F2 1
28 G 1 3
M1 2
F2 1
29 G 3 3
M0 3
F1 2
30 G 1 3
M1 3
F2 2
Desmoid (N =1 ) 3 1 2 3
Chondroblastoma (N =1 ) 3 2 2 2
Table 1. (Continued)
Diagnosis
(number of cases) Case
Score
FAP DPP-IV
Schwannoma (N =3 ) 3 3 0 1
34 0 0
35 1 0
Lipoma (N =1 ) 3 6 0 0
Elastoﬁbroma (N =1 ) 3 7 0 0
Osteoid osteoma (N =1 ) 3 8 3 3
Granulation tissues 3 3
Evaluation method for HER2 immunoreactivity was adopted
for semiquantiﬁcation. Pleomorphic malignant ﬁbrous histi-
ocytoma is also referred to as ‘undifferentiated pleomorphic
high-grade sarcoma’.
F, ﬁbroblastic area; O, osteoblastic area; C, chondroblastic
area; G, giant cells; M, mononuclear cells; FAP, ﬁbroblast
activation protein; DPP-IV, dipeptidylpeptidase-IV.
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sarcomas and ﬁbroblastic areas of osteosarcoma abun-
dantly expressed FAP and DPP-IV. The positivity for
FAP and DPP-IV in MFH could be related to the
previous demonstration of myoﬁbroblastic differentia-
tion in storiform–pleomorphic MFH.
23,24 In sharp
contrast, negative tumours in the present study showed
other differentiation phenotypes. Chondroblastic and
osteoblastic areas of osteosarcoma, both apparently
showing different phenotypes, showed weak expression
of FAP and DPP-IV. No expression was observed in
Ewing’s sarcoma or rhabdomyosarcoma, and the two
sarcomas are thought to be derived from a different cell
lineage: Ewing’s sarcoma is considered to be of neuro-
HE FAP DPP-IV IgG1
Figure 2. Immunohistochemistry in low-grade myoﬁbroblastic sarcoma, showing strong positivity for both ﬁbroblast activation protein (FAP)
and dipeptidylpeptidase-IV (DPP-IV). IgG1, negative control. Scale bar, 50 lm.
DPP-IV FAP HE
Figure 3. Immunohistochemistry of a ﬁbroblastic area of an osteosarcoma. Fibroblast activation protein (FAP) and dipeptidylpeptidase-IV (DPP-
IV) are strongly positive. Scale bar, 25 lm.
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25 and rhabdomyosarcoma of striated
muscle origin. Therefore, our data indicate that FAP
and DPP-IV are positive in an activated ﬁbro-
blast ⁄ myoﬁbroblast-like lineage, and negative in other
cell lineages, including osteoblastic cells (Table 1).
We then considered the relationship to the malig-
nant potential of the tumours, given that both FAP and
DPP-IV are serine integral membrane proteinases. This
suggests their involvement in cancer invasion and
metastasis. However, as shown below, the situation is
rather complicated. Cheng et al.
13 indicated that FAP is
a tumour promoter, whereas Ramirez-Montagut
et al.
12 have described FAP as a tumour suppressor.
Ariga et al.
8 reported that the degree of FAP expression
in breast cancer stromal cells was associated with a
longer survival of patients, and they suggested that
DPP-IV FAP HE
Figure 4. Immunohistochemistry of an osteoblastic area of an osteosarcoma. Fibroblast activation protein (FAP) and dipeptidylpeptidase-IV
(DPP-IV) are weakly positive in the osteoblastic area. Scale bar, 25 lm.
DPP-IV FAP HE IgG1
Figure 5. Immunohistochemistry in Ewing’s sarcoma. Tumour cells, small and round in shape, are negative for ﬁbroblast activation protein
(FAP) and dipeptidylpeptidase-IV (DPP-IV). Stromal cells in septal areas are positive for FAP and DPP-IV (marked with a star). Scale bar, 50 lm.
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cancer stroma. The situation for DPP-IV is similar. On
the one hand, DPP-IV has been reported to play
important roles in metastasis of cancer cells.
14 DPP-IV
is involved with endothelial cell functions as an
adhesion receptor for ﬁbronectin on cancer cells.
20
The expression of ﬁbronectin correlates with the ability
of cancer cells to bind to DPP-IV and metastasize to the
lung.
20 The ability of breast cancer cells to capture
ﬁbronectin molecules suggests that DPP-IV–ﬁbronectin
binding may be a relatively common mechanism
necessary for lung metastasis.
20 On the other hand,
DPP-IV may act as a tumour suppressor by regulating
levels of E-cadherin in cells through an unknown
mechanism.
15 Overall, the signiﬁcance of FAP and
DPP-IV in cancer invasion and metastasis is contro-
versial. Our results indicate that both malignant and
benign tumours express FAP and DPP-IV. Therefore,
DPP-IV IgG1 FAP
Figure 6. Immunohistochemistry of a giant cell tumour. Fibroblast activation protein (FAP) is expressed in spindle-shaped ﬁbroblastic cells,
whereas dipeptidylpeptidase-IV (DPP-IV) is positive in giant cells. Scale bar, 25 lm.
DPP-IV FAP IgG1
Figure 7. Immunohistochemistry of a non-ossifying ﬁbroma. Spindle-shaped tumour cells express both ﬁbroblast activation protein (FAP) and
dipeptidylpeptidase-IV. Scale bar, 25 lm.
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malignant potential of the tumour as far as bone and
soft tissue tumours are concerned.
In addition to the above-mentioned expression in
ﬁbroblastic cells, DPP-IV is associated with another
notable result of this study. Giant cells in giant cell
tumours of bone were positive for DPP-IV. Giant cell
tumours were formerly named osteoclastomas, and
there has been debate concerning the relationship
between giant cells in giant cell tumours and osteo-
clasts. Osteoclasts in normal bone tissue resemble
macrophages in their histogenesis and function,
26
and they are positive for DPP-IV.
18 Therefore, it is
probable that in addition to ﬁbroblastic cells, DPP-IV is
also positive in cells of the monocyte–macrophage
system. DPP-IV expression in reactive giant cells of
osteosarcoma further supports this notion.
In conclusion, both FAP and DPP-IV are expressed in
tumour cells that are histogenetically related to
activated ﬁbroblasts and ⁄ or myoﬁbroblasts, and their
expression is not dependent on the malignancy of
tumours. Our data suggest that FAP and DPP-IV can be
used as markers of activated ﬁbroblasts and ⁄ or myo-
ﬁbroblasts. DPP-IV may also be used as a marker of
cells in the monocyte–macrophage lineage.
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